Biomed Green LLC. focuses on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems.
We are utilizing cannabinoids as the Active Pharmaceutical Ingredients (APIs) to develop synthetic pharmaceuticals in strict accordance with U.S. FDA pre-clinical and clinical pathways.
Our flagship R&D programs are advancing formulations that have the potential to significantly improve the treatment of neurodegenerative disease such as Alzheimer’s, Parkinson’s and ALS.
Developing, licensing and commercializing cannabinoid-based medications for neurodegenerative diseases and other unmet needs.
Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries. Our intent is that any medications we develop will be physician prescribed.
The development and licensing of proprietary nanotechnology drug delivery systems for cannabinoid medications. Biomed’s nanomaterial-controlled release technology, the MICROS Infusion System has been approved for marketing in the US. It provides for the accurate infusion of cannabinoid API’s for human and applications.
Forming strategic collaboration and joint venture with manufacturing companies of cannabis products.
For further information about our products, please contact us. Contact us
Traneuroci™ or NA-831 provides neuroprotection and catalyzing the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed.
Learn more
Biomed Digital is harnessing the power of wearable technology and machine learning to create a digital phenotype that helps clinicians to diagnose early onset of Alzheimer’s disease.
Learn more
Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also conduct Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19
Learn more
Vineurocin (NA-704) is an injectable drug, to regenerate new neurons, and reducting of muscular spasticity, a strong candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.
Learn more
Combination therapy of NA-831 and an antiviral drugs such as Atazanavir, Remdesivir (Gilead Sciences) and anti-inflammatory such as Dexaneurosone and Ivermectin can enhance the effectiveness of the treatment of Covid-19.
Learn more